Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cencora, Inc. Market Cap
Based on ratings from 17 stock analysts, the Cencora, Inc. stock price is expected to increase by 12.71% in 12 months. This is calculated by using the average 12-month stock price forecast for Cencora, Inc.. The lowest target is $230 and the highest is $302. Please note analyst price targets are not guaranteed and could be missed completely.
About 17 Wall Street analysts have assignedCOR 9 buy ratings, 7 hold ratings, and 1 sell ratings. This means that analysts expect Cencora, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on COR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of COR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Rodgers Baird | Outperform | $292 | Maintains | Nov 7, 2024 |
| Kevin Caliendo UBS | Buy | $285 | Maintains | Nov 7, 2024 |
| Stephanie Davis Barclays | Overweight | $290 | Maintains | Nov 7, 2024 |
| John Belton Evercore ISI Group | Outperform | $285 | Maintains | Nov 7, 2024 |
| John Belton Evercore ISI Group | Outperform | $250 | Maintains | Oct 8, 2024 |
| Michael Cherny Leerink Partners | Outperform | $275 | Maintains | Oct 7, 2024 |
| Michael Funk B of A Securities | Neutral | $245 | Downgrade | Sep 18, 2024 |
| David Rodgers Baird | Outperform | $283 | Maintains | Sep 6, 2024 |
| Lisa Gill JP Morgan | Overweight | $287 | Maintains | Aug 21, 2024 |
| David Rodgers Baird | Outperform | $287 | Maintains | Aug 1, 2024 |
| Stephen Baxter Wells Fargo | Equal-Weight | $249 | Maintains | Aug 1, 2024 |
| David Rodgers Baird | Outperform | $285 | Maintains | Jul 9, 2024 |
| Michael Cherny Leerink Partners | Outperform | $275 | Maintains | Jun 27, 2024 |
| David Rodgers Baird | Outperform | $277 | Maintains | May 2, 2024 |
| Michael Rollins Citigroup | Buy | $280 | Maintains | Apr 30, 2024 |
| Michael Cherny Leerink Partners | Outperform | $261 | Initiates | Feb 26, 2024 |
| Omotayo Okusanya Mizuho | Neutral | $224 | Maintains | Feb 5, 2024 |
| Stephanie Davis Barclays | Overweight | $242 | Initiates | Jan 3, 2024 |
| Eric Luebchow Wells Fargo | Equal-Weight | $213 | Initiates | Dec 14, 2023 |
TD Cowen | Outperform | Maintains | Aug 7, 2023 |
When did it IPO
2023
Staff Count
46,000
Country
United States
Sector/Industry
Healthcare/Medical Distribution
CEO
Dr. Robert P. Mauch Ph.D., PharmD
Market Cap
$45.81B
In 2023, COR generated $262.17B in revenue, which was a increase of 9.89% from the previous year. This can be seen as a signal that COR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Cencora, Inc. closed a public offering totaling $1.8 billion, issuing senior notes with interest rates of 4.625%, 4.850%, and 5.150%, maturing in 2027, 2029, and 2035, respectively.
Why It Matters - Cencora's $1.8 billion bond issuance indicates its capital strategy and financial health, impacting its stock value and investor sentiment towards its growth potential.
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Cencora launched Accelerate Pharmacy Solutions, a portfolio aimed at helping hospitals optimize operations and improve financial performance through integrated pharmacy and supply chain solutions.
Why It Matters - Cencora's launch of Accelerate Pharmacy Solutions signals potential revenue growth and market expansion, enhancing operational efficiency for healthcare clients, which can boost investor confidence.
Thu, 05 Dec 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Cencora is highly efficient, generating significant free cash flow with low margins. Its low-cost operations and negative net working capital position it well for growth despite inflation risks.
Why It Matters - Cencora's strong cash flow, efficient capital use, and resilience against inflation enhance its growth potential, making it an attractive investment despite low margins.
Mon, 02 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Premium research service offers Zacks Style Scores, aiding value, growth, and momentum investors in identifying strong stocks.
Why It Matters - Zacks Style Scores enhance stock selection for various investment strategies, potentially leading to better returns and informed decision-making for investors.
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Cencora, Inc. priced $1.3 billion in senior notes: $500M at 4.625% due 2027, $600M at 4.850% due 2029, and $700M at 5.150% due 2035.
Why It Matters - Cencora, Inc.'s bond offerings indicate its funding strategy and debt levels, impacting cash flow and financial stability, which are critical for assessing investment risks and returns.
Mon, 25 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Premium research service offers Zacks Style Scores, aiding value, growth, and momentum investors in identifying strong stocks.
Why It Matters - The Zacks Style Scores enhance stock selection, offering investors valuable insights for identifying strong stocks across different investment strategies, potentially improving portfolio performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
